2,856 results match your criteria Squamous Cell Carcinoma of the Urinary Bladder


Locally advanced squamous cell carcinoma of the vulva: A challenging question for gynecologic oncologists.

Gynecol Oncol 2020 Jul 25;158(1):208-217. Epub 2020 May 25.

Department of Gynecologic Surgery, IRCCS European Institute of Oncology, University of Milan, Milan, Italy. Electronic address:

Squamous cell carcinoma of the vulva is a rare female malignancy, with an incidence increasing with age. Unfortunately, one third of the patients are diagnosed with locally advanced disease, which constitutes a clinical challenge for the clinicians who treat these patients. The main challenges are represented by: 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.05.021DOI Listing

Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder.

Eur J Surg Oncol 2020 May 12. Epub 2020 May 12.

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Background: Radical cystectomy (RC) is often performed for T1 variant histology bladder cancer (VHBC), based on weak clinical evidence. We tested for cancer specific survival (CSS) differences after RC between T1 VHBC vs. urothelial carcinoma of the urinary bladder (UBC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2020.05.006DOI Listing

Portal Vein Thrombosis Associated with Trousseau Syndrome due to Urinary Bladder Squamous Cell Carcinoma in a Liver Cirrhosis Patient.

Intern Med 2020 May 23. Epub 2020 May 23.

Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.

A 75-year-old woman with liver cirrhosis was admitted for treatment of portal vein thrombosis (PVT). Computed tomography (CT) showed PVT, massive ascites, and multiple abdominal organ embolism. Blood tests revealed a decreased liver function (Child-Pugh grade C). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.4112-19DOI Listing

Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study.

World J Urol 2020 May 18. Epub 2020 May 18.

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.

Purpose: To test the effect of perioperative chemotherapy (CHT) on overall mortality (OM) and cancer-specific mortality (CSM) in patients with locally advanced or metastatic squamous cell carcinoma of the urinary bladder (SCC UB).

Methods: Within the Surveillance, Epidemiology and End Results database (1988-2016), we identified 1,018 SCC UB patients (664 TNM, 197 TanyNM and 156 TN or M), who underwent radical cystectomy with or without perioperative chemotherapy administration. Inverse probability of treatment-weighting (IPTW), Kaplan-Meier plots and Cox-regression models (CRMs) were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-020-03247-3DOI Listing

Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma.

Transl Androl Urol 2020 Apr;9(2):428-436

Department of Urology, Peking University First Hospital and Institute of Urology, National Research Center for Genitourinary Oncology, Beijing 100034, China.

Background: Non-schistosoma-associated urinary bladder squamous cell carcinoma (SqCC) has low incidence and is associated with chronic inflammation. Due to its unique etiology and pathology, expression of programmed cell death ligand 1 (PD-L1) in SqCC could be different from that of urothelial carcinoma, which may contribute to different responses to immunotherapy. In this study, we intended to explore the expression profile and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder SqCC under the consideration of tumor-infiltrating lymphocytes' (TILs) density. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2020.02.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215043PMC

Urinary hyaluronic acid: a versatile marker of bladder cancer.

Int Urol Nephrol 2020 May 1. Epub 2020 May 1.

Department of Urology, Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Purpose: To evaluate the role of urinary hyaluronic acid (HA) as a diagnostic marker in urothelial carcinoma (UCC), squamous cell carcinoma (SCC), and adenocarcinoma (ADC) of urinary bladder and compare it with urine cytology.

Methods: HA was estimated in 170 subjects divided into three groups. Group I: UCC 88 patients, 28 with SCC and 12 with ADC; group II: 34 patients with benign bladder tumors; and group III: 10 healthy bladders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11255-020-02480-4DOI Listing

Urethral carcinoma: A compilation of case studies and research findings.

Urol Case Rep 2020 Jul 3;31:101169. Epub 2020 Apr 3.

Medical College of Georgia, USA.

There are three major recognized histological types for primary urethral carcinoma (PUC). These include transitional cell carcinoma (55%), squamous cell carcinoma (21.5%), and adenocarcinoma (16. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eucr.2020.101169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154991PMC

Differentiation of Urothelial Carcinoma into Two Distinct Subtypes, Glandular and Squamous, in Three Different Organs.

Cureus 2020 Mar 15;12(3):e7280. Epub 2020 Mar 15.

Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, LBN.

Urothelial carcinoma (UC) is a unique entity with different histological variants: squamous, glandular, small cell, micropapillary, sarcomatoid, and plasmacytoid. Each of those subtypes behaves differently. As such, and in many scenarios, an accurate histological diagnosis is of paramount importance to dictate the therapeutic approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158603PMC

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.

BMC Cancer 2020 Mar 18;20(1):230. Epub 2020 Mar 18.

Institute of Pathology, University Hospital RWTH Aachen University, Aachen, Germany.

Background: Immune checkpoint inhibitors (ICI) are an integral part of bladder cancer therapy, however, the relevance of ICI treatment for mixed and pure squamous cell carcinoma of the bladder remains poorly studied. Therefore, we analysed the expression of programmed death-ligand 1 (PD-L1) in urothelial carcinomas with squamous differentiation (UC/SCC) and pure squamous cell carcinoma (SCC) of the bladder and studied a UC/SCC patient with ICI therapy.

Methods: Tissue microarrays of 45 UC/SCC and 63 SCC samples were immunohistochemically stained with four anti-PD-L1 antibodies (28-8, 22C3, SP142 and SP263). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-06727-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079494PMC

Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes.

Int J Urol 2020 May 14;27(5):402-407. Epub 2020 Mar 14.

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Québec, Canada.

Objectives: To analyze contemporary multimodality treatment rates, defined as radical cystectomy plus chemotherapy and/or radiotherapy, for pT2-3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients. Additionally, we tested for the effect of multimodality treatment versus radical cystectomy alone on cancer-specific mortality.

Methods: Within the Surveillance, Epidemiology and End Results database (2004-2015), 887 pT2-3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients treated with radical cystectomy were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.14206DOI Listing

Vesical schistosomiasis and squamous cell carcinoma associated with schistosoma haematobium: A re-emerging neglected tropical disease in Tehran, Iran.

Urol Case Rep 2020 May 21;30:101140. Epub 2020 Feb 21.

Department of Parasitology and Mycology, School of Medicine, Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Hematobium species of this parasite tends to bladder and mesenteric arteries and it causes lesions in the bladder wall, urethra, and renal tubes. A 25-year-old man living in Tehran (a non-endemic and very rare area for schistosoma) suffers from symptoms such as hematuria with suprapubic pain, dysuria, fever, nausea and vomiting. Urine analysis showed a lot of red blood cells, after using cystoscopy of the area and receiving a bladder biopsy, a definitive diagnosis of schistosomiasis was made and after determining the extent of damage to the urinary tract, appropriate treatment with surgery and praziquantel (40 mg/kg) were prescribed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eucr.2020.101140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044752PMC

[Urinary bladder cancer as a late sequela of spinal cord injury : Decision-making aids for assessment of this causal association].

Urologe A 2020 Jun;59(6):700-709

Zentrale Einrichtung Klinische Arbeitsmedizin, Leibniz-Institut für Arbeitsforschung an der TU Dortmund (IfADo), Dortmund, Deutschland.

Background: There is to date no convincing literature that has assessed the association between traumatic spinal cord injury (SCI) and the later development of urinary bladder cancer. The aim of this work is to present medical experts as well as the national accident insurance and the social courts decision-making aids based on the latest medical scientific knowledge, for assessment of this causal association.

Materials And Methods: A study conducted between April 1998 and March 2017 in the BG Trauma Hospital Hamburg forms the basis for the decision-making aids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00120-020-01124-wDOI Listing

Bladder Stones Associated with an Aggressive Plasmacytoid Variant of Urothelial Cancer: A Rare Case and Literature Review.

Curr Urol 2020 Jan 7;13(4):217-223. Epub 2020 Jan 7.

Department of Urology, Princes Alexandra Hospital, Harlow, UK.

Urothelial carcinoma is the most common histologic subtype of bladder cancer, accounting for approximately 90%. We herein report a case of a 78-year-old man with an unusual association of bladder stones with an aggressive plasmacytoid variant of urothelial cancer. Initially he presented in 2009 with a very large bladder stone and was treated by an open cystolithotomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977006PMC
January 2020

Human papillomavirus and urinary bladder cancer revisited.

APMIS 2020 Feb 28;128(2):72-79. Epub 2020 Jan 28.

Department of Urology, Aarhus University Hospital, Aarhus, Denmark.

This review aims to present data on the association between human papillomavirus (HPV) and urinary bladder cancer (BC), especially of the subtype squamous cell carcinoma (SCC). Furthermore, the current data on the relation between p16, HPV, and BC are reviewed. PubMed was searched for 'Humans' [MESH] AND 'Papillomaviridae' [MESH] AND 'Urinary Bladder Neoplasms' [MESH], resulting in 157 potential articles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apm.13016DOI Listing
February 2020

Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.

J Urol 2020 Jul 23;204(1):63-70. Epub 2020 Jan 23.

Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington.

Purpose: Urinary tract cancer can be pure urothelial carcinoma, pure nonurothelial carcinoma or variant urothelial carcinoma (defined here as mixed urothelial carcinoma). Little is known regarding outcomes for patients with variant urothelial carcinoma receiving immune checkpoint inhibitors. We hypothesized that variant urothelial carcinoma does not compromise immune checkpoint inhibitor efficacy in patients with advanced urothelial carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000761DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289665PMC
July 2020
4.471 Impact Factor

[Development of a squamous cell carcinoma of the urinary bladder after intravesical condylomas].

Aktuelle Urol 2020 Jan 15. Epub 2020 Jan 15.

MVZ OptiPath, Pathologie, Frankfurt am Main.

Background:  The occurrence of intravesical condylomata acuminata has been described as a fairly uncommon, benign epithelial lesion. Reports on progression into a muscle-invasive carcinoma of the bladder are rare.

Case:  We present the case of a 68-year-old man who had a history of intravesical condylomata acuminata over several years and developed a muscle-invasive squamous cell carcinoma of the bladder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0761-2593DOI Listing
January 2020

Traumatic spinal cord injury confers bladder cancer risk to patients managed without permanent urinary catheterization: lessons from a comparison of clinical data with the national database.

World J Urol 2020 Jan 13. Epub 2020 Jan 13.

Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), Dortmund, Germany.

Purpose: Life expectancy for people with traumatic spinal cord injury (SCI) is increasing due to advances in treatment methods and in neuro-urology. Thus, developing urinary bladder cancer (UBC) is gaining importance.

Methods: Single-centre retrospective evaluation of consecutive in- and out-patient data with spinal cord injury between January 1st, 1998 and December 31st, 2018 was carried out and data were compared with UBC data of the German population from the German Centre for Cancer Registry Data at Robert Koch Institute. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-020-03077-3DOI Listing
January 2020

A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.

Proc Natl Acad Sci U S A 2020 01 23;117(1):563-572. Epub 2019 Dec 23.

Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095;

Small cell carcinoma of the bladder (SCCB) is a rare and lethal phenotype of bladder cancer. The pathogenesis and molecular features are unknown. Here, we established a genetically engineered SCCB model and a cohort of patient SCCB and urothelial carcinoma samples to characterize molecular similarities and differences between bladder cancer phenotypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1915770117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955337PMC
January 2020

Step by step Indiana pouch construction in a previously irradiated patient with a cervical cancer relapse.

Int J Surg Case Rep 2020 9;66:187-191. Epub 2019 Dec 9.

Multidisciplinary Unit for Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellon, Spain; Dept. of Medicine, University Jaume I (UJI), Castellon de la Plana, Spain.

Introduction: Radiation therapy and radical pelvic surgery, either radical cystectomy or pelvic exenteration, is the golden standard treatment for infiltrating bladder carcinoma, as well as advanced or recurrent cervical, vulvar, vaginal and endometrial cancer. However, due to the poor radiation sensitivity of the cervix and vagina, a high-radiation dose is required, leading to early and/or late onset urogenital complications in approximately 50% of the patients.

Case Presentation: The following case report describes a 64-year-old native Russian woman presenting a relapse of a vaginal cuff squamous cell carcinoma, who underwent a laterally extended endopelvic resection (LEER) followed by a neobladder reconstruction based on the Indiana pouch (IP) technique. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2019.11.068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928324PMC
December 2019

Urinary tract infections and risk of squamous cell carcinoma bladder cancer: A Danish nationwide case-control study.

Int J Cancer 2020 04 8;146(7):1930-1936. Epub 2020 Jan 8.

Department of Clinical Epidemiology, Institute of Clinical Medicine, Arhus University Hospital, Aarhus, Denmark.

Schistosoma haematobium infection can lead to squamous cell carcinomas (SCC) of the bladder. Whether this also applies to more common urinary tract infections (UTIs) is unclear. We therefore aimed to investigate the association between UTIs, reflected by the use of specific antibiotics and risk of SCC of the bladder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32842DOI Listing

A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab.

BMC Urol 2019 Dec 9;19(1):128. Epub 2019 Dec 9.

Department of Translational Research and New Technologies in Medicine and Surgery, Sections of Urology, University of Pisa, via Paradisa 2, 56126, Pisa, Italy.

Background: The angiogenesis inhibitor monoclonal antibody Bevacizumab is presently the standard treatment for numerous neoplasms but particular toxicities are emerging, such as hypertension, haemorrhage, thromboembolism, gastrointestinal perforation, fistulae, and delayed wound healing. The addition of Bevacizumab to radio and chemotherapy has improved the overall survival rate in patients with metastatic, persistent or recurrent cervical carcinoma. However an increased risk of enteric or urinary fistula formation has been documented, related to hypoxia which is induced by the inhibition of angiogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12894-019-0566-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902463PMC
December 2019

Nomograms to predict individual prognosis of patients with squamous cell carcinoma of the urinary bladder.

BMC Cancer 2019 Dec 9;19(1):1200. Epub 2019 Dec 9.

Department of Urology, Qilu Hospital of Shandong University, No. 107 West Wenhua Road, Jinan, Shandong Province, China.

Background: On the basis of some significant clinical parameters, we had an intent to establish nomograms for estimating the prognosis of patients with squamous cell carcinoma of the urinary bladder (SCCB), including overall survival (OS) and cancer-specific survival (CSS).

Methods: The data of 1210 patients diagnosed with SCCB between 2004 and 2014,were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The Cox proportional hazards regression model was applied to evaluate the association between variables and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-6430-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902456PMC
December 2019

Rapid testicular metastasis from bladder transitional urothelial carcinoma after radical cystoprostatectomy: A case report.

Medicine (Baltimore) 2019 Nov;98(48):e18000

Department of Urology.

Rationale: Bladder cancer (BC) is commonly diagnosed in the urinary system and the most common subtype is transitional urothelial carcinoma (TCC). Even with the best treatment, tumor recurrence and metastases always occur. While clinicians commonly observe the metastases to pelvic lymph nodes, liver, lung, and bone, it may infrequently spread to some uncommon locations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000018000DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890337PMC
November 2019

Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis.

World J Urol 2019 Nov 20. Epub 2019 Nov 20.

Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St., ASB II-3, Boston, MA, 02115, USA.

Background: The impact of variant histologies on overall survival (OS), as well as their influence on the response to neoadjuvant and adjuvant chemotherapy (AC) is well studied in patients diagnosed with bladder cancer. However, little is known about tumors with variant histologies of the upper urinary tract. The objective of this study was to assess the survival of the predominant variant histologies of tumors of the renal pelvis (RPT) after surgical intervention, and to examine the influence of AC on the OS of the different variant histologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-019-03003-2DOI Listing
November 2019
5 Reads

Updates on the Genomics of Bladder Cancer and Novel Molecular Taxonomy.

Adv Anat Pathol 2020 Jan;27(1):36-43

Department of Pathology, University of Alabama at Birmingham, Birmingham, AL.

Urothelial carcinoma (UC) is the most common malignant neoplasm of the bladder that encompasses a wide spectrum of histopathologic features and various molecular alterations and subtypes, responsible for its significant morphologic and genomic heterogeneity. Morphologically, in addition to classic UC (not otherwise specified), many well documented variant histologies are a common finding in invasive UC, and include squamous, glandular, micropapillary, sarcomatoid, small cell/neuroendocrine, clear cell, lymphoepithelioma-like, and plasmacytoid types, among others. This review provides an update on the recent advances in the molecular characterization and novel molecular taxonomy of UC and variant histologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000252DOI Listing
January 2020

Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data.

PLoS One 2019 7;14(11):e0224143. Epub 2019 Nov 7.

MINES ParisTech, PSL Research University, CBIO-Centre for Computational Biology, Paris, France.

Tumors are made of evolving and heterogeneous populations of cells which arise from successive appearance and expansion of subclonal populations, following acquisition of mutations conferring them a selective advantage. Those subclonal populations can be sensitive or resistant to different treatments, and provide information about tumor aetiology and future evolution. Hence, it is important to be able to assess the level of heterogeneity of tumors with high reliability for clinical applications. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0224143PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837753PMC

Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.

Int J Oncol 2019 Dec 7;55(6):1372-1384. Epub 2019 Oct 7.

Department of Oncology‑Pathology, Karolinska Institutet, 171 74 Stockholm, Sweden.

Fibroblast growth factor receptor (FGFR)3 and phosphatidylinositol‑4,5‑bisphosphate 3‑kinase, catalytic subunit alpha (PIK3CA) mutations are found in various types of cancer, such as urinary bladder cancer, human papillomavirus‑positive tonsillar and base of the tongue squamous cell carcinoma, breast cancer and some childhood sarcomas. Several drugs can target these genes, some of which have been used for the treatment of urinary bladder cancer. Much less is known about childhood cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2019.4896DOI Listing
December 2019
1 Read

Eruptive squamous cell carcinoma in a patient treated with concomitant pembrolizumab and imiquimod.

J Dermatol 2019 Dec 9;46(12):1202-1204. Epub 2019 Oct 9.

Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Pembrolizumab, a humanized monoclonal antibody against programmed cell death 1, is used for various malignant neoplasms. Toll-like receptor (TLR) agonists, specifically targeting the TLR9 subfamily (TLR7-9), are treatment options for solid tumors and hematological malignancies. We experienced a case of eruptive squamous cell carcinoma (SCC) in a patient treated concomitantly with pembrolizumab and imiquimod, a TLR7 agonist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15101DOI Listing
December 2019
1 Read

A single-institute experience of trimodal bladder-preserving therapy for histologic variants of urothelial carcinoma.

Int J Clin Oncol 2020 Feb 8;25(2):354-361. Epub 2019 Oct 8.

Department of Urology, University of Tsukuba, 1-1-1 Ten-nodai, Tsukuba, Ibaraki, 305-8575, Japan.

Background: We retrospectively evaluated the clinical outcomes of patients with histologic variants of muscle invasive bladder cancer (MIBC) treated with trimodal bladder-preserving therapy (TMT).

Methods: Among 148 patients with clinical T2-3N0M0 MIBC treated with TMT at Tsukuba University Hospital from 1990 to 2015, 11 patients (7.4%) had pathological components of variant urothelial carcinoma (UC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01553-4DOI Listing
February 2020

Cytological and Wet Mount Microscopic Observations Made in Urine of -Infected Children: Hint of the Implication in Bladder Cancer.

Can J Infect Dis Med Microbiol 2019 2;2019:7912186. Epub 2019 Sep 2.

Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.

Background: Schistosomiasis is the second major human parasitic disease next to malaria, in terms of socioeconomic and public health consequences, especially in sub-Saharan Africa. () is a trematode and one of the species of that cause urogenital schistosomiasis (urinary schistosomiasis). Although the knowledge of this disease has improved over the years, there are still endemic areas, with most of the reported cases in Africa, including Ghana. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7912186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745107PMC
September 2019
3 Reads

Impact of CT-based brachytherapy in elderly patients with cervical cancer.

Brachytherapy 2019 Nov - Dec;18(6):771-779. Epub 2019 Sep 7.

QST Hospital, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.

Purpose: Three-dimensional image-guided brachytherapy (3D-IGBT) has become the standard therapy for patients with cervical cancer. However, in this population, the impact of 3D-IGBT in elderly individuals remains unknown. This study assessed the efficacy of 3D-IGBT for elderly patients with cervical cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2019.08.002DOI Listing
April 2020
4 Reads

Comparative analysis of genitourinary function after type C1 robotic nerve-sparing radical hysterectomy versus type C2 robotic radical hysterectomy.

Surg Oncol 2019 Sep 11;30:58-62. Epub 2019 May 11.

Department of Gynecologic Oncology and Robotic Surgery, Center of Hope, University of Nevada, Reno School of Medicine, Reno, NV, USA. Electronic address:

Background: To compare the return of bladder function and genitourinary complications after type C1 robotic nerve-sparing radical hysterectomy (C1-RRH) to type C2 robotic radical hysterectomy (C2-RRH) in gynecologic cancers.

Methods: A retrospective analysis between C1-RRH (n = 42) and C2-RRH (n = 43) was performed. Operative outcomes and perioperative genitourinary complications between the two groups were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.suronc.2019.05.003DOI Listing
September 2019
1 Read
3.270 Impact Factor

Impact of lymph node dissection in radical cystectomy for bladder cancer: How many vs how far?

Surg Oncol 2019 Sep 28;30:109-116. Epub 2019 Jun 28.

Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. Electronic address:

Purpose: To determine whether the extent or number of lymph nodes (LNs) is important in muscle-invasive bladder cancer and high-risk non-muscle-invasive bladder cancer patients' oncologic outcomes.

Methods: A total of 448 patients who underwent radical cystectomy with lymphadenectomy of standard, extended, and super-extended template were included. Exclusion criteria were neoadjuvant chemotherapy and limited lymphadenectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.suronc.2019.06.008DOI Listing
September 2019
2 Reads

Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.

Ann Diagn Pathol 2019 Dec 3;43:151397. Epub 2019 Aug 3.

Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. Electronic address:

Background: Genomic studies have delineated distinct molecular subgroups of urothelial carcinomas whose prognostic impact extends beyond traditional stage and grade groupings. The 'basal' subgroup shows increased gene expression levels of KRT5, KRT6, and KRT14 and low expression levels of GATA binding protein 3, and is associated with an extremely poor outcome. Identification of this subset is necessary for improved patient management and research on targeted therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2019.08.001DOI Listing
December 2019
1 Read
1.112 Impact Factor

Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma.

BMC Cancer 2019 Aug 14;19(1):806. Epub 2019 Aug 14.

Department of Urology, Medical Faculty, Heinrich Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

Background: Few diagnostic and prognostic biomarkers are available for head-and-neck squamous cell carcinoma (HNSCC). Long non-coding RNAs (lncRNAs) have shown promise as biomarkers in other cancer types and in some cases functionally contribute to tumor development and progression. Here, we searched for lncRNAs useful as biomarkers in HNSCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-6021-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694542PMC
August 2019
3 Reads

A clinicopathological and immunohistochemical study of non-urothelial bladder tumours.

Indian J Cancer 2019 Jul-Sep;56(3):254-260

Department of Pathology, Bhopal Memorial Hospital and Research Centre (Under Department of Health Research), Bhopal, Madhya Pradesh, India.

Background: Non-urothelial bladder tumors (NUBTs) are uncommon accounting for approximately 10% of the total urinary bladder tumors while 90% are urothelial in origin. There are very limited comprehensive studies on NUBTs.

Aims And Objectives: The objectives of the study were to analyze the clinicopathological and immunohistochemical features of NUBTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijc.IJC_459_17DOI Listing
January 2020
6 Reads

Revisiting cercariform cells: Small cell carcinoma masquerading as cercariform cells.

Diagn Cytopathol 2019 Oct 6;47(10):1072-1075. Epub 2019 Aug 6.

The Leopold G. Koss Department of Cytopathology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York.

Cercariform cells are slender cells with a bulbous end and a unipolar long cytoplasmic process, resembling Schistosoma cercariae. Since their first description in urothelial carcinoma, multiple studies have attempted to explore their utility in distinguishing metastatic urothelial carcinoma from other common malignant neoplasms, such as adenocarcinoma and squamous-cell carcinoma. Although not pathognomonic, they are most commonly encountered in urothelial carcinoma, but they can also be seen in other neoplasms, raising the possibility that this cytomorphological feature can be exploited to aid in diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.24296DOI Listing
October 2019

Condyloma Acuminatum of Urinary Bladder: Relation to Squamous Cell Carcinoma.

Am J Surg Pathol 2019 11;43(11):1547-1553

Departments of Pathology.

Condyloma acuminatum rarely occurs in the urinary bladder and is considered to be a risk factor for squamous cell carcinoma, although there are only a few publications with limited cases. We studied 51 cases of condyloma acuminatum of the urinary bladder from transurethral resections of the urinary bladder of 38 patients from the consult files of one of the authors. Transurethral resections of the urinary bladder were obtained from 25 males with a median age of 73 years (range: 41 to 87 y) and 13 females with a median age of 68 years (range: 30 to 86 y). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001339DOI Listing
November 2019
6 Reads

Cervical Cancer Staging in Saudi Arabia Clinicoradiological Correlation.

Authors:
Nisreen Anfinan

Biomed Res Int 2019 23;2019:8745828. Epub 2019 Jun 23.

Gynecology Oncology Unit, Department of Obstetrics and Gynaecology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Objective: The aim of this study was to compare the finding of pelvic MRI with clinical staging using cystoscopy and sigmoidoscopy for cervical cancer patients.

Method: We reviewed all patients with cervical cancer between January 2001 and December 2015. We correlate the clinical examination, cystoscopy, and sigmoidoscopy with MRI findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8745828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612378PMC
December 2019
1 Read

Differential responses of epithelial cells from urinary and biliary tract to eggs of Schistosoma haematobium and S. mansoni.

Sci Rep 2019 07 24;9(1):10731. Epub 2019 Jul 24.

Department of Microbiology, Immunology & Tropical Medicine, and Research Center for the Neglected Diseases of Poverty, School of Medicine and Health Sciences, George Washington University, Washington DC, USA.

Chronic urogenital schistosomiasis can lead to squamous cell carcinoma of the bladder. The International Agency for Research on Cancer classifies the infection with S. haematobium as a group 1 carcinogen, a definitive cause of cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-46917-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656753PMC
July 2019
1 Read

Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.

Histopathology 2020 Jan 9;76(2):191-200. Epub 2019 Sep 9.

Dpartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Aims: Programmed death-ligand 1 (PD-L1) expression by tumour cells (TC) is a mechanism for tumour immune escape through down-regulation of antitumour T cell responses and is a target for immunotherapy. PD-L1 status as a predictor of treatment response has led to the development of multiple biomarkers with different reference cut-offs. We assessed pathologist consistency in evaluating PD-L1 immunopositivity by examining the inter- and intraobserver agreement using various antibody clones and different cancer types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917963PMC
January 2020
5 Reads

Malignancies of suprapubic catheter (SPC) tracts in spinal cord injury patients: a case series and review of literature.

Spinal Cord Ser Cases 2019 15;5:34. Epub 2019 Apr 15.

Salisbury District Hospital, Odstock Road, Salisbury, SP28BJ UK.

Introduction: Spinal cord injury (SCI) patients are at increased risk of bladder cancer. A rare variation of this is a malignancy arising or including the suprapubic catheter (SPC) tract.

Case Series: We present the first case series of malignancy of the SPC tract in SCI patients, including a case of mucinous adenocarcinoma, squamous cell carcinoma and sarcoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41394-019-0177-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474306PMC
June 2020
5 Reads

Sexual, bladder, bowel and ovarian function 1 year after robot-assisted radical hysterectomy for early-stage cervical cancer.

Acta Obstet Gynecol Scand 2019 11 12;98(11):1404-1412. Epub 2019 Aug 12.

Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

Introduction: Surgery by open radical hysterectomy for cervical cancer is associated with sexual dysfunction as well as lymphedema and bladder problems. Our aim was to assess the impact of robot-assisted laparoscopic radical hysterectomy (RRH) with pelvic lymphadenectomy for early-stage cervical cancer on sexual, bowel, bladder, and lymphatic function and to measure ovarian function after RRH.

Material And Methods: Twenty-six women with early-stage cervical cancer during 2011-2013 were investigated before and 1 year after RRH using a validated questionnaire measuring psychological well-being and sexual, bowel, bladder, and lymphatic function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.13680DOI Listing
November 2019
8 Reads

Molecular pathology of the luminal class of urothelial tumors.

J Pathol 2019 11 27;249(3):308-318. Epub 2019 Aug 27.

Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.

Molecular subtypes of urothelial carcinoma may be divided into luminal and nonluminal tumors. Nonluminal tumors are composed of cases with basal/squamous-like or small cell/neuroendocrine features, with a consensus on the molecular characteristics of the respective subtype. In contrast, luminal tumors are more disparate with three to five suggested subtypes and with definitions that do not always cohere. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851980PMC
November 2019
11 Reads

Inflammation-associated pathologies in a case of prostate schistosomiasis: Implications for a causal role in prostate carcinogenesis.

Prostate 2019 08 18;79(11):1316-1325. Epub 2019 Jun 18.

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Background: Urogenital infection with Schistosoma haematobium is a risk factor for the development of squamous cell carcinoma of the urinary bladder. The pathophysiology is thought to be mediated in part by inflammation, cellular damage, and bladder regeneration induced by the parasitic infection. Herein, we report an unusual case of schistosomiasis of the prostate that was found concurrent with prostate adenocarcinoma in a radical prostatectomy specimen from a man in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23841DOI Listing
August 2019
12 Reads

Head and neck squamous cell carcinoma and metachronous second primaries.

Eur Ann Otorhinolaryngol Head Neck Dis 2019 Oct 14;136(5):367-372. Epub 2019 Jun 14.

ENT and Head & Neck Surgery Department, University Hospital Centre, 80054 Amiens cedex 1, France. Electronic address:

Objectives: To assess the rate of second (or more) primaries after treatment for head and neck squamous cell carcinoma (HNSCC), and survival compared to patients with a single head and neck cancer.

Material And Method: A single-center retrospective study was performed in a University Hospital Center in 541 patients between 2002 and 2010.

Results: One hundred and forty-one patients (26. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anorl.2019.05.006DOI Listing
October 2019
5 Reads

Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes.

Eur Urol Oncol 2019 05 13;2(3):239-247. Epub 2018 Sep 13.

Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. Electronic address:

Context: In the past few years, research has suggested that molecular subtypes in muscle-invasive bladder cancer (MIBC) may be exploited to accelerate developments in clinical disease management and novel therapeutics.

Objective: To review MIBC mouse models from a molecular subtype perspective, their advantages and limitations, and their applications in translational medicine, based on a PubMed search for publications from January 2000 to February 2018.

Evidence Acquisition: Publications relevant to MIBC mouse models and their molecular subtypes were identified in a literature review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.08.014DOI Listing
May 2019
8 Reads

Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.

J Clin Pathol 2019 Aug 4;72(8):550-553. Epub 2019 Jun 4.

Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA

Aims: To describe a large tertiary care academic centre's experience with patients who achieve a complete pathological response (ie, ypT0N0) following neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) with emphasis on morphological features present in the RC and clinical outcome.

Methods: 41 patients with ypT0N0 disease following transurethral resection of bladder tumour (TURBT), NAC and RC with available clinical follow-up information were analysed. Slides from all RCs were reviewed to confirm pathological stage and assess for morphological parameters (eg, foreign body giant cell reaction, dystrophic calcification, scar and fat necrosis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2019-205742DOI Listing
August 2019
10 Reads

Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project.

Eur Urol Oncol 2018 10 5;1(5):437-442. Epub 2018 Jun 5.

Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy.

Background: It has been shown that active surveillance (AS) is feasible and effective in a subset of patients with recurrent low-grade (LG) non-muscle-invasive bladder cancer (NMIBC).

Objective: To update a previous preliminary series and investigate pathological outcomes for patients who failed to remain on AS.

Design, Setting, And Participants: Prospective observational cohort study started in February 2008, and currently still active, at a tertiary university hospital, including patients with pathologically confirmed NMIBC who experienced recurrence during follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.05.006DOI Listing
October 2018
15 Reads

Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.

Eur Urol Oncol 2018 09 17;1(4):307-313. Epub 2018 Jul 17.

Department of Urology, Meir Medical Center, Kfar Saba, Israel.

Background: The highly frequent strategy of surveillance for non-muscle-invasive bladder cancer (NMIBC) involves cystoscopy and cytology. Urine assays currently available have not shown performance sufficient to replace the current gold standard for follow-up, which would require a very high negative predictive value (NPV), especially for high-grade tumors. Bladder EpiCheck (BE) is a novel urine assay that uses 15 proprietary DNA methylation biomarkers to assess the presence of bladder cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.06.011DOI Listing
September 2018
3 Reads